VivoSeq
Psychiatry

Psychosis

90

Pipeline Programs↗

32

Active Trials↗

40

Companies Involved↗

Psychosis is a moderately active landscape with 90 programs across 40 companies. The most active players are Viatris Specialty LLC, Bayer, Triax. 28 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

41/100

Mech. Concentration

11/100

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1T

Triax

1 program

Phase 1Biogen logo

Biogen

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical13

Methylphenidate

Novartis

Immunoglobulin

Sanofi

Antidepressant

Johnson & Johnson

Treatment as Usual

AB Biotics, SA

Antipsychotic Drugs

Johnson & Johnson

Phase 112

Ocrelizumab

Roche

Gabapentin

Viatris Specialty LLC

Aspirin

Bayer

Memantine

AbbVie

Minocycline

Triax

Phase 220

Sodium Benzoate

Liminal BioSciences Ltd.

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Rituximab

Roche

Levetiracetam

UCB

Ketamine Hydrochloride

Boehringer Ingelheim

Phase 317

Cannabidiol

Jazz Pharmaceuticals

N-Acetylcysteine

Novartis

Fluoxetine

Vitae Pharmaceuticals Inc., an Allergan affiliate

Modafinil

Nuvo Research GmbH

Karxt

Bristol-Myers Squibb

Approved28

Risperidone

Wim Janssens

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Brexpiprazole

Otsuka

Olanzapine

MODAG GmbH

Asenapine

AbbVie

Analysis

Modality Breakdown

98%

Small molecule

94 of 96 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody22%

Small molecule leads; the ring shows all 96 classified programs, each share of the total. Modality classified for 99% of 99 pipeline programs.

Analysis

Trial Status

131

clinical trials

Completed74 · 56%
Recruiting13 · 10%
Not yet recruiting12 · 9%
Terminated11 · 8%
Unknown status9 · 7%
Active, not recruiting5 · 4%
Other7 · 5%

Clinical Trials

Trial Activity

131 trials

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Recruiting·MMapLight Therapeutics·Phase 2·NCT06887192·300 enrolled
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Recruiting·JJohns Hopkins University·Phase 2·NCT05824728·30 enrolled
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
Recruiting·UUniversity of Cambridge·Phase 2·NCT03194815·70 enrolled
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Recruiting·—·Phase 1·NCT04789915·46 enrolled
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Recruiting·VVA Office of Research and Development·Phase 4·NCT04373317·358 enrolled
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk
Recruiting·KKing's College London·N/A·NCT06224530·69 enrolled
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting·KKaruna Therapeutics·Phase 3·NCT05511363·410 enrolled
Cognitive Strategies in Early Psychosis 1
Recruiting·UUniversity of Minnesota·Phase 3·NCT07231497·103 enrolled
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Recruiting·UUniversity of California, San Diego·Phase 3·NCT04411225·120 enrolled
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Recruiting·MMonument Therapeutics Limited·Phase 1/2·NCT07226895·150 enrolled
ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruiting·AACADIA Pharmaceuticals Inc.·Phase 2/3·NCT06159673·1,074 enrolled
Culturally-adapted Cognitive-behavioural Therapy for Black Sub-Saharan African and Caribbean People Experiencing Psychosis: A Case Series
Recruiting·UUniversity of Manchester·Preclinical·NCT07252206·6 enrolled
Mentalization Based Treatment (MBT) in Help Seeking Youths With a Clinical High-Risk Condition for Psychosis (CHR-P): a Randomized Controlled Trial
Recruiting·—·Preclinical·NCT07093671·212 enrolled
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
Active, not recruiting·YYale University·Phase 1·NCT02102113·21 enrolled
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
Active, not recruiting·UUniversity of Alabama at Birmingham·N/A·NCT03442101·156 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)